ACCESS Newswire
13 Jan 2022, 18:35 GMT+10
JACKSON CENTER, PA / ACCESSWIRE / January 13, 2022 / Halberd, Inc. (OTC PINK:HALB) ('HALB' or the 'Company'), an innovative biotech company focused on developing treatments for difficult-to-cure debilitating diseases, today announces that they have been able to successfully eliminate Beta Amyloid and Interleukin-4 (IL-4) from synthetic cerebral spinal fluid (CSF) in its latest in-vitro laboratory testing. The Company's latest testing accomplishments support its long-standing goal of successfully eradicating all of the top ten target antigens from a static sampling of CSF, thereby permitting control of these target antigens to the prescribed homeostasis level under physician care. Our progress is illustrated in the table below linked to neurodegenerative diseases which have remained virtually untreated over the centuries.
Top Ten Neurological Target Antigens
Proof of Eradication from CSF Results
Top Ten Neurological Pathogens and Target Antigens
Proof of Eradication from CSF Results
N/A - indicates antigen is not associated with specified condition.
* Includes Alzheimer's, Parkinson's, Epilepsy & Lou Gehrig's Disease.
N/A - indicates antigen is not associated with listed condition
** - Includes Alzheimer's, Parkinson's, Epilepsy, and ALS
Dr. Mitchell S. Felder, HALB's Chief Technology Officer and a board-certified attending neurologist stated, 'Beta-Amyloid is widely recognized to be a major factor of Alzheimer's Disease. Halberd's unique ability to eradicate Beta-Amyloid, coupled with its eradication of IL-4 and its previous elimination of TNF-Alpha, Phosphorylated-Tau, other target antigens, and inflammatory cytokines from CSF, leads the Company to believe it has achieved unparalleled progress toward slowing or preventing the onset of Alzheimer's Disease and other neurodegenerative diseases, such as Epilepsy, Lou Gehrig's Disease (ALS), PTSD, Traumatic Brain Injury, and Chronic Traumatic Encephalopathy. Although comparative, competitive data has been difficult to obtain, we believe that this is a truly spectacular result in comparison to any other competitive claimed therapies available anywhere in the world. The best we can determine from competition is that they claim to eliminate only 5-15% of Beta-Amyloid from CSF within a month of expensive treatment.'
'Our successful in-vitro laboratory tests prove our technology can be used to regulate any of the top ten neurodegenerative linked targeted antigens to acceptable levels, as directed by attending physicians,' stated William A. Hartman, HALB's Chairman, President, & CEO. 'The significance of these continuing series of tests is that Halberd's three issued patents as well as its 20 related provisional patent applications prove that this unique technology belongs exclusively to Halberd Corporation.'
About Halberd, Inc. (HALB)
Halberd, Inc. (the 'Company') is an innovative biotech company focused on developing treatments through its acquired exclusive licenses, patents, and provisional patent applications for illnesses including and limited to; PTSD, CTE, cancer, blood-borne, and cerebrospinal fluid related diseases. To learn more, please visit https://halberdcorporation.com.
SAFE HARBOR ACT: Forward-looking statements are included within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding the Company's expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations or listing on an exchange - including words such as 'anticipate,' 'if,' 'believe,' 'plan,' 'estimate,' 'expect,' 'intend,' 'may,' 'could,' 'should,' 'will' and other similar expressions - are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond the Company's control and may cause actual results, performance or achievements to differ materially from anticipated results, performance or achievements. The Company is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise. No information in this press release should be construed in any manner whatsoever as an indication of the future performance of the Company's revenues, financial condition or stock price.
Company Contact:
William A. Hartman
Chairman, President, & CEO
814.786.8849 Office
SOURCE: Halberd Corporation
Get a daily dose of Albuquerque Express news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Albuquerque Express.
More InformationEVERGLADES, Florida: Over the weekend, a diverse coalition of environmental activists, Native American leaders, and residents gathered...
BEIJING, China: China's national soccer team may struggle to stir excitement, but its humanoid robots are drawing cheers — and not...
]LONDON, U.K.: A World Health Organization (WHO) expert group investigating the origins of the COVID-19 pandemic released its final...
DOVER, Delaware: California Governor Gavin Newsom has taken legal aim at Fox News, accusing the network of deliberately distorting...
FRANKFURT, Germany: Germany has become the latest country to challenge Chinese AI firm DeepSeek over its data practices, as pressure...
TORONTO, Canada: Harvard University and the University of Toronto have created a backup plan to ensure Harvard graduate students continue...
NEW YORK, New York - Global stock indices closed with divergent performances on Tuesday, as investors weighed corporate earnings, central...
TORONTO, Canada: Canadian Prime Minister Mark Carney announced late on June 29 that trade negotiations with the U.S. have recommenced...
Vancouver, Canada: A high-stakes legal showdown is brewing in the world of athleisure. Lululemon, the Canadian brand known for its...
LONDON, U.K.: British oil giant Shell has denied reports that it is in talks to acquire rival oil company BP. The Wall Street Journal...
NEW YORK, New York - U.S. stock markets closed firmly in positive territory to start the week Monday, with the S&P 500 and Dow Jones...
WASHINGTON, D.C.: On Friday, President Donald Trump announced that he was halting trade discussions with Canada due to its decision...